


Image



PATENT
Customer Number: 22,852
Attorney Docket No. 4853.0068-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Katsuhiko MIKOSHIBA et al.) Group Art Unit: 1647
)
Application No.: 09/832,189) Examiner: Sharon L. Turner
)
Filed: April 11, 2001)
)
For: TRUNCATED REELIN PROTEIN)
AND DNA ENCODING THE SAME)

Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the document listed on the attached Form PTO 1449. This Information Disclosure Statement is being filed, to the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application.

The document was cited in the prosecution of co-pending and possibly related Application Serial No. 09/897,438. While Applicants believe that the Examiner is aware of this document, Applicants provide it now for the Examiner's specific consideration and to ensure that the file is complete.

Applicants respectfully request that the Examiner consider the document and indicate that it was considered by making appropriate notations on the attached form.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed document is material or constitutes "prior art." If the Examiner applies the document as prior art against any claim in the application and Applicants determine that the cited document does not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the document.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed document, should the document be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,


FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: December 23, 2003

By: Jean B. Fordis
Jean B. Fordis
Reg. No. 32,984

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	4853.0068-00000	Serial No.	09/832,189
Applicant	Katsuhiko MIKOSHIBA et al.		
Filing Date	April 11, 2001	Group:	1647

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue/ Publication Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	de Bergeyck, V. et al., 1998, "A panel of monoclonal antibodies against reelin, the extracellular matrix protein defective in reeler mutant mice," J. of Neuroscience Methods, 82: 17-24.

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce